Cargando…

Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience()

BACKGROUND: Long-term data on the effectiveness and safety of the booster dose of anti-SARS-CoV-2 vaccines in people affected by multiple sclerosis (pwMS) are lacking, hence a retrospective monocentric study exploring these issues was undertaken. MATERIALS AND METHODS: PwMS who had received the boos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertozzi, Andrea, Mariottini, Alice, Marchi, Leonardo, Cristinzi, Maria Di, Nistri, Riccardo, Damato, Valentina, Mechi, Claudia, Barilaro, Alessandro, Massacesi, Luca, Repice, Anna Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957336/ https://www.ncbi.nlm.nih.gov/pubmed/36889098 http://dx.doi.org/10.1016/j.msard.2023.104582

Ejemplares similares

Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance
por: Mariottini, Alice, et al.
Publicado: (2022)

Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy
por: Clausi, Valeria, et al.
Publicado: (2015)

Safety and tolerability of SARS‐Cov‐2 vaccination in patients with myasthenia gravis: A multicenter experience
por: Farina, Antonio, et al.
Publicado: (2022)

The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies
por: Amoriello, Roberta, et al.
Publicado: (2020)

Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update
por: Mariottini, Alice, et al.
Publicado: (2023)

Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis
por: Massacesi, Luca, et al.
Publicado: (2022)

Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis
por: Amoriello, Roberta, et al.
Publicado: (2022)

Case report: 3D intracranial vessel wall MRI in Susac syndrome: potential relevance for diagnosis and therapeutic management
por: Lotti, Antonio, et al.
Publicado: (2023)

TCR repertoire diversity in Multiple Sclerosis: High-dimensional bioinformatics analysis of sequences from brain, cerebrospinal fluid and peripheral blood
por: Amoriello, Roberta, et al.
Publicado: (2021)

Long-term-video monitoring EEG and 18F-FDG-PET are useful tools to detect residual disease activity in anti-LGI1-Abs encephalitis: A case report
por: Cornacchini, Sara, et al.
Publicado: (2022)

Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies
por: Maggi, Pietro, et al.
Publicado: (2018)

CSF/serum matrix metallopeptidase‐9 ratio discriminates neuro Behçet from multiple sclerosis
por: Aldinucci, Alessandra, et al.
Publicado: (2018)

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
por: Ruggieri, Serena, et al.
Publicado: (2023)

Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
por: Massacesi, Luca, et al.
Publicado: (2014)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT
por: Bonechi, Elena, et al.
Publicado: (2014)

Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
por: Ziello, Antonio, et al.
Publicado: (2021)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
Publicado: (2022)

Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine
por: Breetz, Katherine A, et al.
Publicado: (2022)

COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience
por: Preziosa, Paolo, et al.
Publicado: (2020)

Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances
por: Mariottini, Alice, et al.
Publicado: (2023)

PB2605: EFFICACY AND SAFETY OF MRNA COVID VACCINES IN ITP PATIENTS: A MONOCENTRIC REAL-LIFE STUDY
por: D’angelo, Simona, et al.
Publicado: (2023)

Antibody-mediated cell depletion therapies in multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Volatilome Analysis in Prostate Cancer by Electronic Nose: A Pilot Monocentric Study
por: Filianoti, Alessio, et al.
Publicado: (2022)

mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks, and Coverage
por: Nashwan, Abdulqadir J., et al.
Publicado: (2022)

Abstract #1403045: Thyroiditis Post COVID-19 mRNA Booster Dose Vaccination
por: Seow, Cherng Jye
Publicado: (2023)

Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis
por: Amoriello, Roberta, et al.
Publicado: (2021)

SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
por: Di Giacomo, Anna M., et al.
Publicado: (2022)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
por: Mengesha, Bethlehem, et al.
Publicado: (2022)

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
por: Grewal, Ramandip, et al.
Publicado: (2023)

Ictal apnea: A prospective monocentric study in patients with epilepsy
por: Micalizzi, Elisa, et al.
Publicado: (2022)

Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022
por: Gálvez, Jubby Marcela, et al.
Publicado: (2023)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience
por: Baratè, Claudia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_978d99su4stenjeit5k6t02uou